Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Classifica tra le azioni #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Prezzo delle azioni
$58.70
Ultima sincronizzazione: 2024-01-23
Capitalizzazione di mercato
$2.98B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Mirati Therapeutics, Inc. (MRTX)

Categoria

Storico del prezzo dell'azione per Mirati Therapeutics, Inc. (MRTX)
Prezzo di chiusura più alto: $58.94 il 2024-01-01

Prezzo di chiusura più basso: $8.67 il 2013-07-01
Storico del prezzo dell'azione di Mirati Therapeutics, Inc. dal 2013 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 2.02%
2023 12.06%
2022 -63.56%
2021 -39.15%
2020 103.16%
2019 189.49%
2018 132.29%
2017 218.41%
2016 -84.08%
2015 98.82%
2014 1.02%
2013 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.50 -12.74%
AU
$764.47 7.08%
CH